Project

A Study to Evaluate Imetelstat (GRN163L) in Transfu-sion-Dependent Subjects with IPSS Low or Intermedi-ate-1 Risk Myelodysplastic Syndrome (MDS) that is Re-lapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Scheduled · 2021 until 2030

Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Scheduled
Start Date
2021
End Date
2030
Financing
Others
Study Design
Phase III
Keywords
MDS, lower risk, Imetelstat, anemia, transfusion-dependency
Brief description/objective

A Study to Evaluate Imetelstat (GRN163L) in Transfu-sion-Dependent Subjects with IPSS Low or Intermedi-ate-1 Risk Myelodysplastic Syndrome (MDS) that is Re-lapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment